Sernova Corp (TSE:SVA) has released an update.
Sernova Corp., a clinical-stage biotech firm, reports promising results in Type 1 Diabetes (T1D) treatment with their Cell Pouch system showing successful islet engraftment and sustained insulin independence in a patient for four years. The company also plans to file an IND application for a new hypothyroidism treatment in 2024, as it continues to expand its pipeline focusing on endocrine disorders. Recent trials have shown improved outcomes with an advanced immunosuppression protocol, leading to minimal side effects and no signs of graft rejection.
For further insights into TSE:SVA stock, check out TipRanks’ Stock Analysis page.
